{"title":"Upsher-Smith to Take Over CNS Partner Proximagen","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1761","DOIUrl":null,"url":null,"abstract":"Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"31 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1761","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Upsher-Smith Laboratories has agreed to acquire the 84% of its CNS partner Proximagen that it does not already own in a deal worth up to £356.8 M (US$554 M). For each Proximagen share, Upsher-Smith will pay £3.20, which represents a 16% premium over Proximagen’s closing price prior to the announcement of the transaction. The deal also includes contingent value rights relating to the success of two Proximagen compounds: the Phase I vascular adhesion protein-1 (VAP1) inhibitor for rheumatoid arthritis and PRX00933, which has completed Phase II development for the treatment of obesity
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
